title: Integrin VLA-5 negative primary plasma cell leukemia.
abstract: We present a case of primary plasma cell leukemia with Bence Jones proteinuria. After combination chemotherapy, leukemic cells and the urinary levels Bence Jones protein were decreased. Small lytic bone lesions were detected only in the skull. Typical plasma cells were rarely seen in peripheral blood on the hyperleukocytic phase, however they were increased in the advanced stages. The most important diagnostic sign was persistent expression of CD38 antigen on leukemic cells throughout the entire course of the illness and these leukemic cells expressed very late antigen-4 (VLA-4) but not VLA-5.
authors.affiliation: Second Department of Internal Medicine, Saitama Medical Center, Saitama Medical School, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Ohtake
authors.forename: T
authors.initials: T
authors.lastname: Takeuchi
authors.forename: K
authors.initials: K
authors.lastname: Saito
authors.forename: T
authors.initials: T
authors.lastname: Ito
authors.forename: I
authors.initials: I
authors.lastname: Ito
authors.forename: K
authors.initials: K
authors.lastname: Aoki
authors.forename: Y
authors.initials: Y
authors.lastname: Takano
authors.forename: K
authors.initials: K
authors.lastname: Amano
authors.forename: O
authors.initials: O
authors.lastname: Hosono
authors.forename: J
authors.initials: J
authors.lastname: Koide
mesh_terms: D036541:ADP-ribosyl Cyclase; D051997:ADP-ribosyl Cyclase 1; D000368:Aged; D015703:Antigens, CD; D000943:Antigens, Differentiation / Q000032:analysis; D000951:Antigens, Neoplasm / Q000032:analysis; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001536:Bence Jones Protein / Q000652:urine; D001853:Bone Marrow / Q000473:pathology; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007952:Leukemia, Plasma Cell / Q000175:diagnosis / Q000188:drug therapy / Q000378:metabolism* / Q000652:urine; D008562:Membrane Glycoproteins; D009363:Neoplasm Proteins / Q000172:deficiency* / Q000652:urine; D014411:Neoplastic Stem Cells / Q000737:chemistry* / Q000473:pathology; D010014:Osteolysis / Q000209:etiology; D011239:Prednisolone / Q000008:administration & dosage; D017469:Receptors, Fibronectin / Q000172:deficiency*; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D015703:Antigens, CD; D000943:Antigens, Differentiation; D000951:Antigens, Neoplasm; D008562:Membrane Glycoproteins; D009363:Neoplasm Proteins; D017469:Receptors, Fibronectin; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D001536:Bence Jones Protein; D011239:Prednisolone; D036541:ADP-ribosyl Cyclase; C498154:CD38 protein, human; D051997:ADP-ribosyl Cyclase 1